Switch to desktop

Home

V. Virology (Non-HIV), Including Resistance, and Non-HIV Viral Opportunistic Infections in HIV-Infected Patients

Meet-the-Experts

CMV Persistent Viremia: What Does it Mean?

The goal of this session is to discuss the clinical significance of persisting herpes virus viremia detected by sensitive molecular tools.

Upon completion of this Meet-the-Experts Session, the participant should be able to:

Identify what is a relevant persisting viremia for CMV and EBV;
Identify the clinical relevance of this viremia; and
Discuss the different monitoring tools and the treatment options.

Experts:
Upton D. Allen, MD, MBBS; Hosp. for Sick Children, Univ. of Toronto, Toronto, Canada.
Paul Griffiths, MD, DSE; Univ. Coll. London, UCL Med. Sch., London, United Kingdom.

New Strategies for Transplantation of HIV Infected Individuals

This session will focus on management strategies in HIV patients undergoing transplantation. The discussion will focus on complex patient management strategies in the current era of transplantation. Specifically the session will review the impact of drug interactions on HIV-infected transplant recipients. The safety and efficacy of HIV infected donors for HIV-infected renal transplant recipients will also be reviewed.

Upon completion of this Meet-the-Experts Session, the participant should be able to:

Analyze the impact of drug interactions (with a focus on antiretrovirals and immunosuppressants) on patient management; and
Assess the safety of HIV infected donor organs in HIV-infected transplant recipients.

Experts:
Linda Frassetto, MD; Univ. of California, San Francisco, CA.
Elmi Muller, MBChB, MRC; Univ. of Cape Town, Groote Schuur Hosp., Cape Town, South Africa.

Symposia

Hot Topics in Viral Hepatitis

This session will review new developments in Hepatitis both in the normal and immunosuppressed host. Hepatitis B, C, and E will be reviewed. Newer therapeutics will be discussed and treatment approaches will include the management of Hepatitis and HIV coinfection. The epidemiology of Hepatitis E will also be reviewed.

Upon completion of this Symposium Session, the participant should be able to:

Differentiate treatment options for Hepatitis B and C for unique patient populations including HIV coinfected patients and transplant recipients;
Formulate appropriate treatment plans for Hepatitis viruses in different patient populations, recognizing the impact of drug interactions; and
Describe the epidemiology of Hepatitis E and assess treatment options in normal and immunosuppressed hosts.

Conveners:
Emily A. Blumberg, MD; Perelman Sch. of Med., Univ. of Pennsylvania, Philadelphia, PA.
Jean-michel G. Molina, MD; Hosp. Saint Louis, Univ. of Paris 7, Paris, France.

Presentations:
Hepatitis C: Impact of New and Future Therapeutics
Norah Terrault, MD, MPH; Univ. of California, San Francisco, CA.

Hepatitis B: Management of Mono and HIV Co-Infected Individuals
Douglas T. Dieterich, MD; Mount Sinai Sch. of Med., New York, NY.

Epidemiology and Management of the Normal and Immunosuppressed Host with Hepatitis E
Nassim Kamar, MD, PhD; Toulouse Univ. Hosp., Toulouse, France.

Influenza: Beyond the Headlines

This symposium will review new influenza threats including evolving situations with the 2009 H1N1 pandemic virus, the highly pathogenic H5N1 virus in Asia and recent swine H3N2 virus transmission in humans. The epidemiological features, clinical manifestations and available therapeutic and prophylactic modalities for these influenza viruses will be reviewed in details.

Upon completion of this Symposium Session, the participant should be able to:

Describe the epidemiological features of selected influenza virus threats;
Assess the mechanisms responsible for severe influenza diseases;
Identify risk factors for severe influenza infections; and
Discuss potential therapeutic and prophylactic modalities for specific influenza variants.

Conveners:
Guy Boivin, MD; Laval Univ., Quebec, Canada.
Vincent Racaniello, PhD; Columbia Univ., New York, NY.

Presentations:
Severe Influenza during the Pandemic: Why was the Disease so Variable?
Peter J. Openshaw, MB, MS, BSc, PhD, FRCP; Imperial Coll., London, United Kingdom.

H5N1 Influenza Viruses in Asia and Middle-East: Still a Threat?
Malik Peiris, MBBS, PhD; Hong Kong Univ., Hong Kong, Hong Kong.

Emergence of an Animal-Origin Influenza A H3N2 Virus in the US
Lyn Finelli, PhD; CDC, Atlanta, GA.

Recognizing and Managing Antiviral Resistance

Antiviral resistance is an increasing problem for many clinically-significant viruses such as the human immunodeficiency virus (HIV), cytomegalovirus (CMV), influenza viruses and hepatitis B virus (HBV). This symposium will review the incidence of drug-resistant viruses, the risk factors for acquisition, the clinical consequences associated with resistant infections and potential management strategies.

Upon completion of this Symposium Session, the participant should be able to:

Discuss the increasing problem of antiviral resistance;
Identify risk factors for selecting for drug-resistant viruses;
Discuss the consequences of drug-resistant infections; and
Propose potential alternate therapeutic strategies.

Conveners:
Guy Boivin, MD; Laval Univ., Quebec, Canada.
Joseph Eron Jr., MD; Univ. of North Carolina, Chapel Hill, NC.

Presentations:
Management of HIV Resistance: New Perspectives
Ian Frank, MD; Univ. of Pennsylvania, Philadelphia, PA.

CMV: When to Think About Resistance and When to Switch Therapy?
Sunwen Chou, MD; Oregon Hlth. and Sci. Univ., Portland, OR.

Influenza: How Resistance Emerges and the Role of Combination Therapy
Maria Zambon, PhD; Hlth. Protection Agency, London, United Kingdom.

How to Avoid Resistance When Treating Hepatitis B
Lorne Tyrell, MD; Univ. of Alberta, Edmonton, Canada.

Viruses and the Central Nervous System: Diagnostic, Treatment and Recent Outbreaks

Upon completing of this session the participants should learn the major characteristics and limitations of diagnostic tools for herpes meningo-encephalitis and learn how to use available treatments. Discuss the impact of emerging enteroviruses.

Upon completion of this Symposium Session, the participant should be able to:

Describe clinical features of medically important herpes viruses and associated meningo-encephalitis;
Describe the potential advantages and limitation of available diagnostic procedures;
Discuss the role of the different treatment options; and
Describe the role of emerging enteroviruses.

Conveners:
Laurent Kaiser, MD; Univ. Hosp. of Geneva, Geneva, Switzerland.
Morven S. Edwards, MD; Baylor Coll. of Med., Houston, TX.

Presentations:
VZV CNS Complications
Anne Gershon, MD; Columbia Univ. Med. Ctr., New York, NY.

HHV6 Encephalitis in Immunocompetent and in Immunocompromised Hosts
Danielle Zerr, MD, MPH; Univ. of Washington, Seattle Children’s Hosp., Seattle, WA.

HSV Central Nervous System Infection in Neonates and Children: Diagnostic and Treatment Monitoring
David W. Kimberlin, MD; Univ. of Alabama, Birmingham, AL.

Enterovirus 71 and Brainstem Encephalitis in Asia
Mong How Ooi, MRCP, PhD; Sarawak Gen. Hosp., Sarawak, Malaysia.

Interactive Symposium

Transplantation and the ID Physician: Management Strategies for the 21st Century

This session will focus on diagnostics and management strategies in transplant recipients. Topics will include fungal and viral diagnostics and include a discussion of the limitations of the laboratory. Functional immune assays will be critically reviewed. Finally the impact of immunological assessment and diagnostic strategies on prophylactic strategies will be assessed.

Upon completion of this Interactive Symposium Session, the participant should be able to:

Analyze the utility and limitations of viral diagnostics in transplant recipients;
Assess the optimal use of fungal diagnostics in the management of transplant recipients;
Identify when to use immune monitoring assays in transplant recipients; and
Demonstrate how diagnostic assays may impact on prophylactic strategies in transplant recipients.

Conveners:
Emily A. Blumberg, MD; Perelman Sch. of Med., Univ. of Pennsylvania, Philadelphia, PA.
Jay A. Fishman; Massachusetts Gen. Hosp., Harvard Med. Sch., Boston, MA.

Presentations:
Viral Molecular Diagnostics: How Reliable are the Results?
Ajit P. Limaye, MD; Univ. of Washington, Seattle, WA.

Laboratory Monitoring for Fungi in Transplantation: Advantages and Limitations
Barbara Alexander, MD, MHS; Duke Univ., Durham, NC.

Functional Immune Assays and the Individualization of Care
Atul Humar, MD, MSc, FRCPC; Univ. of Alberta, Edmonton, Canada.

Immunologically Based Prophylactic Strategies in Transplant Recipients
Jay A. Fishman, MD; Massachusetts Gen. Hosp., Harvard Med. Sch., Boston, MA.

Top Desktop version